ORIC Pharmaceuticals, Inc. — Form 8-K Summary
Report date: March 21, 2022. The filing concerns a conference call and webcast discussing fourth-quarter and full-year 2021 financial results and providing an operational update. ORIC is a Delaware corporation headquartered in South San Francisco, California, and its common stock trades on Nasdaq under the symbol ORIC.
Financial and Operating Information
The filing text provided does not include specific revenue, net loss, cash flow, cash balance, margins, debt, liquidity, or other financial metrics. It also does not provide the details of the operational update.
Material Changes and Outlook
No specific period-over-period changes, guidance, outlook, management commentary, risks, contingencies, or unusual items are included in the filing text provided. These matters may be addressed in the referenced corporate presentation.
Filing Items
- Item 7.01: Regulation FD disclosure regarding the March 21, 2022 conference call and webcast.
- Exhibit 99.1: Corporate presentation dated March 21, 2022.
- Exhibit 104: Cover Page Interactive Data File.
- The disclosures under Items 7.01 and 9.01, including Exhibit 99.1, were furnished and were not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.
Facts Investors Should Verify
- Review Exhibit 99.1 for the fourth-quarter and full-year 2021 financial results and operational update.
- Verify cash, liquidity runway, operating expenses, research and development spending, and any financing or debt information in the presentation or related filings.
- Assess any disclosed clinical, regulatory, development, or business milestones and associated risks.
- Confirm whether management provided forward-looking guidance or timing expectations.